VERA - CIK 0001831828
The table below shows Vera Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $86.01M | $56.47M | $58.20M | $41.28M | $40.31M | $29.31M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $39.12M |
| $27.46M |
| $21.95M |
| $15.92M |
| $9.49M |
| $8.03M |
| Operating income | -$125.13M | -$83.93M | -$80.14M | -$57.19M | -$49.80M | -$37.34M |
| Income tax | - | - | - | - | - | - |
| Net income | -$121.03M | -$80.29M | -$76.53M | -$51.69M | -$46.63M | -$33.71M |
| EPS (diluted) | -$1.69 | -$1.26 | -$1.20 | -$0.81 | -$0.85 | -$0.62 |